Halozyme Therapeutics, Inc. (HALO)
$
76.92
-2.59 (-3.37%)
Key metrics
Financial statements
Free cash flow per share
5.1391
Market cap
9 Billion
Price to sales ratio
7.2781
Debt to equity
2.9980
Current ratio
1.5871
Income quality
1.0260
Average inventory
183.7 Million
ROE
1.4155
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally, focusing on advancing drug delivery technologies. The company recorded an operating income of $551,475,000.00 reflecting its earnings from core operations, while incurring an interest expense of $18,095,000.00 indicative of its debt servicing obligations. The total costs and expenses for the company are $463,849,000.00 highlighting its overall spending. Additionally, the diluted EPS is $3.43 accounting for potential share dilution, and the company incurred an income tax expense of $113,041,000.00 indicating its tax obligations. Its flagship product, Hylenex recombinant, utilizes patented recombinant human hyaluronidase enzyme (rHuPH20) to facilitate subcutaneous fluid administration, enhancing the dispersion and absorption of other injected drugs. The company develops several important therapeutics including Perjeta, RITUXAN HYCELA, and MabThera SC for non-Hodgkin lymphoma, as well as HYQVIA for immunodeficiency disorders. Furthermore, collaborations with several renowned organizations support its innovative efforts in treating various conditions. The stock is affordable at $77.81 suitable for budget-conscious investors, which, combined with a high average trading volume of 2,045,971.00 indicates strong liquidity. With a mid-range market capitalization of $9,045,561,240.00 the company is a steady performer in the competitive landscape of the Biotechnology industry. As a key player in this sector, it significantly contributes to the overall market landscape, driving innovation and growth. In addition to its successful products, the company is actively developing treatments such as Tecentriq for non-small cell lung cancer and OCREVUS for multiple sclerosis, alongside other promising therapies aimed at a variety of serious health conditions. Halozyme's extensive collaborations with top pharmaceutical companies also underscore its commitment to addressing unmet medical needs and advancing healthcare outcomes globally.
Is Halozyme Therapeutics, Inc. (HALO) a good investment?
Investing in Halozyme Therapeutics, Inc. (HALO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is Halozyme Therapeutics, Inc. (HALO)'s stock forecast?
Analysts predict Halozyme Therapeutics, Inc. stock to fluctuate between $47.50 (low) and $82.22 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Halozyme Therapeutics, Inc.'s market capitalization?
As of 2026-02-12, Halozyme Therapeutics, Inc.'s market cap is $9,045,561,240, based on 117,597,000 outstanding shares.
How does Halozyme Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Halozyme Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Halozyme Therapeutics, Inc. (HALO) stock?
To buy Halozyme Therapeutics, Inc. (HALO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for HALO. Place an order (Market, Limit, etc.).
What is the best time to invest in Halozyme Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Halozyme Therapeutics, Inc. perform in the last earnings report?
Revenue: $1,015,324,000 | EPS: $3.50 | Growth: 64.32%.
Where can I find Halozyme Therapeutics, Inc.'s investor relations reports?
Visit https://www.halozyme.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Halozyme Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Halozyme Therapeutics, Inc. stock?
All-time high: $82.22 (2026-02-09) | All-time low: $29.85 (2023-05-09).
What are the key trends affecting Halozyme Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
seekingalpha.com
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth
zacks.com
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Halozyme Therapeutics' shares jump nearly 4% after preliminary 2025 results beat expectations and management lifts 2026 outlook.
seekingalpha.com
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript
prnewswire.com
Updates Preliminary Unaudited 2025 Estimates: - Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1 - Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1 Raises 2026 Financial Guidance Ranges: - Increases Total Revenue to $1,710 - $1,810 million, YoY Growth of 23% to 30%2 - Increases Royalty Revenue to $1,130 - $1,170 million, YoY Growth of 30% to 35%2 - Increases Adjusted EBITDA to $1,125 - $1,205 million3,4 - Increases non-GAAP Diluted EPS to $7.75 - $8.253,4 Expands Drug Delivery Opportunity with Acquisition of Surf Bio and its Hyperconcentration Technology Conference Call Scheduled Today at 5:30am PT/8:30am ET SAN DIEGO, Jan. 28, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today provided a business update, including providing preliminary unaudited 2025 revenue estimates and raising full year 2026 and multi-year financial guidance. The Company also announced it acquired Surf Bio, Inc. ("Surf Bio"), a biopharmaceutical company with an innovative, biologic hyperconcentration technology seeking to transform the delivery of antibodies and biologics, in December 2025.
defenseworld.net
Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the thirteen research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and eight have issued a buy
newsfilecorp.com
Calgary, Alberta--(Newsfile Corp. - January 22, 2026) - Cleantek Industries Inc. (TSXV: CTEK) ("Cleantek" or the "Company"), an innovative provider of patented clean technology solutions that reduce both cost and carbon intensity in the wastewater management and industrial lighting sectors, is pleased to announce the award of an international contract for the supply and installation of up to 60 HALO SE Crown Mount lighting systems. The contract follows the successful completion of multiple HALO deployments throughout 2025 and reflects growing international demand for Cleantek's solutions.
fool.com
Explore the exciting world of Halozyme Therapeutics (HALO 0.85%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
See all news
